Clinical trial
Safety of Imovax Polio in Chinese Infants and Children
NCT00258843 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00258843 |
|---|---|
| Title | Safety of Imovax Polio in Chinese Infants and Children |
| Official title | Clinical Safety Evaluation Study of the Sanofi Pasteur's Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) Administered as a Single Booster Dose at 18 Months of Age in Healthy Chinese Children, and as the First Dose of Primary Vaccination at 2 Months of Age in Healthy Chinese Infants. |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Poliomyelitis |
| Intervention type | Biological |
| Interventions | Inactivated Poliomyelitis vaccine |
| Enrollment | 40 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Nov 28, 2005 |
| Last update posted | Jan 22, 2014 |
| Countries | China |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: